Where Will Biogen Be in 5 Years?
Biogen (NASDAQ: BIIB) investors recently received an unwelcome surprise from an important government agency. The phrase "coverage with evidence development" (CED) might not sound too serious, but these words from the Centers for Medicare & Medicaid Services (CMS) were heavy enough to put Biogen's stock price under pressure on Wednesday, Jan. 12, 2022.
The CMS decision was tough on Biogen stock price in the short term, but what do the next five years have in store? Here's what to expect up ahead.
Image source: Getty Images.
Source Fool.com
